Ipilimumab Effective in Adolescents With Advanced Melanoma

Source: Onclive, November 2017

Ipilimumab (Yervoy) was associated with a 1-year overall survival (OS) rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.
Ipilimumab is approved for adult patients, but there is little data regarding the safety and efficacy of the anti-CTLA-4 monoclonal antibody in children or adolescents. To investigate, researchers in the United States and Europe conducted Study CA184-178, a single-arm, multicenter, open-label phase II study of ipilimumab in patients aged 12 to <18 years (N = 12) with previously treated or untreated, unresectable stage III/IV advanced melanoma.
Patients with ocular melanoma, active brain metastases, history of autoimmune disease, or prior therapy with CTLA-4, PD-1, PD-L1, or CD137 targeted agents were excluded.